Efficacy and Safety of Cyclosporine A Microemulsion in Maintenance Patients With Chronic Plaque Psoriasis

Inclusion criteria: * Outpatients 18 years of age and older (max 65 years) * Patients with chronic plaque psoriasis on disease remission (i.e. PASI ≤75% of PASI before cyclosporine continuous treatment course) entering a maintenance period * Disease remission obtained with only cyclosporine as systemic therapy (maximum dose 5 mg/kg/day) for \>8 weeks and \<16 weeks * PASI still \<75% of PASI before cyclosporine continuous treatment course, at randomization to study treatment (8±2 days after disease remission) Exclusion criteria: * Abnormal renal function (creatinine ≥ 10% the upper limit of the reference range) * Severe chronic degenerative diseases * Severe uncontrolled hypertension * Body weigh \>110 kg * Abnormal liver function * Hyperkalemia or hyperuricemia * Clinically significant impairment of hematopoietic and cardiovascular function * Concomitant therapy with nephrotoxic medications * Patients with malignancy or a history of malignancy * Females of childbearing potential who are planning to become pregnant, who are pregnant and/or lactating, who are unwilling to use effective means of contraception * Clinically significant uncontrolled bacterial, viral or fungal infection * Evidence of drug and/or alcohol abuse